Topical Collection "Nanoparticles in Therapeutic Applications"


Guest Editor
Dr. Wassana Yantasee

Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States; President/CEO, PDX Pharmaceuticals, Portland, Oregon, United States
Website 1 | Website 2 | E-Mail
Interests: nanomedicine; RNAi; drug delivery; nanobiotechnology; cancer; fibrosis; metal chelation; pharmaceutical; immunotherapy

Topical Collection Information

Dear Colleagues,

Nanoparticles have garnered intense interest as a therapeutic platform to treat a broad range of diseases, including cancer, metabolic, cardiovascular, skin, renal, inflammatory, and infectious disease. Well-designed nanoparticles can enhance the efficacy of traditional therapeutics through enhanced solubility, prolonged circulation or drug release, targeted delivery to disease sites, and reduced toxicity. Nanoparticles can be formulated for systemic, dermal, oral, and inhalation applications and optimized to overcome the delivery barriers of emerging therapeutics such as oligonucleotides, mRNA, and DNA with the potential to be safer than viral vector counterparts. Nevertheless, like any emerging technology, further advances in research are required to overcome the technological and regulatory barriers if nanoparticles are to fulfil their immense potential for human applications.

In order to offer a publication platform for researchers working in the nanotherapeutic field, the MDPI journal, Bioengineering, is dedicating a Topical Collection to Nanoparticles in Therapeutic Applications and is asking for your valuable contribution. The Issue will focus on nanoparticle development and applications in broad ranges of diseases and delivery routes. Research toward increased understanding of pharmacokinetics, pharmacodynamics, toxicity, stability, and manufacturability of nanoparticles is also highly relevant.

We look forward to receiving your contributions to this Issue of Bioengineering.

Assoc. Prof. Wassana Yantasee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)


Open AccessArticle GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
Bioengineering 2018, 5(4), 83;
Received: 17 August 2018 / Revised: 4 October 2018 / Accepted: 6 October 2018 / Published: 9 October 2018
PDF Full-text (7110 KB) | HTML Full-text | XML Full-text | Supplementary Files
Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific
[...] Read more.
Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific delivery of active pharmaceutical ingredients and facilitates entrapment inside the tumor. Polo-like kinase 1 (PLK-1) inhibitors have shown promising results in tumor cells. GSK461364A (GSK) is one such targeted inhibitor with reported toxicity issues in phase 1 clinical trials. We have demonstrated in our study that the action of GSK is time dependent across all concentrations. There is a distinct 15−20% decrease in cell viability via apoptosis in U87-MG cells dosed with GSK at low concentrations (within the nanomolar and lower micromolar range) compared to higher concentrations of the drug. Additionally, we have confirmed that PLGA-PEG nanoparticles (NPs) containing GSK have shown significant reduction in cell viability of tumor cells compared to their free equivalents. Thus, this polymeric nanoconstruct encapsulating GSK can be effective even at low concentrations and could improve the effectiveness of the drug while reducing side effects at the lower effective dose. This is the first study to report a PLK-1 inhibitor (GSK) encapsulated in a nanocarrier for cancer applications. Full article

Figure 1

Bioengineering EISSN 2306-5354 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top